Mytide, a tech-enabled biotechnology manufacturing services company, appointed Martina Diekmann CEO. She will take over as CEO from Mytide’s founder Dale Thomas, who has been CEO since 2018.

Following Diekmann’s appointment, Thomas will assume the role of chief technology officer with a focus on driving future innovation.

According to the company, Thomas has been instrumental in establishing Mytide, known for its innovative automated peptide manufacturing platform that combines machine learning/AI with robotic systems. In transitioning to the CTO role, Thomas will focus on the company’s continued innovation and further technological development. This decision was made to support Mytide’s strong growth and leverage its proprietary technology into new applications.

Diekmann has previously held several senior executive roles with high growth CRO/CDMO businesses in the life science sector. Most recently she served as CEO of vivitide, a supplier of custom peptides, antibodies and proteomic tools. Prior to that she held management positions at Bachem AG and Solvias AG.

In a statement, the company said that Diekmann’s expertise will be instrumental in driving Mytide’s growth as the company transitions from technology development into production and revenue growth.

“Mytide is building a new 10,000-square-foot production facility in Waltham, which will house our second-generation Biopolymer Fabrication (BioFab) platforms,” said Diekmann. “The build out allows us to scale the manufacturing of peptides throughout 2023/2024 to meet demand.”

“We are currently enrolling new clients in our membership program that has been designed to grant access to the fastest turn-around peptide manufacturing platform on the market,” said Thomas. “It has been proven to provide rapid access to peptides for some of the most exciting drug discovery and biology pipelines, particularly within neoantigen, cell therapy, and vaccine development.”